New Plant Extracts toward Multidrug Resistance: The Convergence of Nanotechnology and Nanoscience

The relentless rise of multidrug-resistant (MDR) pathogens has severely limited the effectiveness of conventional antibiotics, posing a grave threat to public health. While plant extracts have long been recognized as rich reservoirs of bioactive phytochemicals with antimicrobial properties, their clinical translation has been hindered by issues of reproducibility, solubility, stability, and standardization. Nanotechnology and nanoscience hold the potential to overcome these limitations by enabling controlled drug delivery, enhanced bioavailability, and targeted action, thus revitalizing interest in plant-derived antimicrobials. This review critically examines the integration of plant extracts and nanotechnology as a strategy to combat MDR organisms. It provides a balanced perspective, highlighting both the successes and challenges reported in recent studies. Mechanistic insights are offered to explain how nanocarriers—such as liposomes, polymeric nanoparticles, metal nanoparticles, and nanoemulsions—improve the pharmacokinetics and stability of phytochemicals. A comparative overview underscores differences in nanocarrier systems, linking their structural attributes to observed antimicrobial outcomes. Beyond efficacy, the review addresses essential concerns regarding reproducibility, regulatory hurdles, safety assessments, and the environmental impact of large-scale nanoparticle use. It also suggests standardization strategies, advances in analytical characterization, and adoption of green synthesis approaches to ensure sustainability. Ethical considerations, including equitable access and transparent risk communication, are integrated into the discourse. Ultimately, this review aims to guide future research toward the judicious, evidence-based application of plant extract-based nanotherapeutics. By bridging these interdisciplinary domains, it points toward more sustainable, effective, and clinically viable solutions in the ongoing battle against MDR pathogens.